Akums Drugs & Pharmaceuticals Ltd. has secured EU GMP certification for two India plants and entered the UK market with MHRA approval for Rivaroxaban, strengthening its push into regulated European markets.
Lupin has secured European Commission approval for its biosimilar ranibizumab, marking a major step in expanding access to advanced eye care treatments across the European Union.
Dr. Reddy’s Laboratories Ltd. has secured USFDA review for its proposed interchangeable abatacept biosimilar, DRL_AB, positioning itself as the first to file a BLA in this segment and strengthening its biologics footprint in the US market.
BahiaFarma has joined hands with Biocon Biologics and Bionovis to develop and manufacture Pertuzumab for HER2-positive breast cancer, strengthening Brazil’s public healthcare supply and deepening India-Brazil pharma collaboration.
Morepen Laboratories has secured a Rs 825 crore multi-year CDMO contract from a global pharmaceutical company, marking one of its largest mandates and reinforcing its growing presence in global manufacturing partnerships.
Lilly and Company has announced that its Retevmo (selpercatinib) has met its primary endpoint in the LIBRETTO-432 Phase 3 trial, showing a significant improvement in event-free survival for early-stage RET fusion-positive NSCLC patients.
Lonza expands Advanced Synthesis to accelerate ADC and bioconjugate development, integrating GlycoConnect, HydraSpace, dual-payload technology, and scalable CDMO services.
GSK has secured European Commission approval for Exdensur (depemokimab), a twice-yearly treatment for severe asthma and chronic rhinosinusitis with nasal polyps, offering sustained control for patients with uncontrolled type 2 inflammation.
Johnson & Johnson has secured FDA approval for a monthly dosing schedule of RYBREVANT FASPRO, marking a major step forward in first-line treatment for EGFR-mutated advanced non-small cell lung cancer.
Novartis announces sale of 70.68% stake in Novartis India for Rs 1,446 crore, with an offer to buy an additional 26% from public shareholders, marking a major strategic shift.
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")